Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by Sidney Kimmel Comprehensive Cancer Center.
Recruitment status was  Recruiting
Johns Hopkins University
Boston University
Information provided by:
Sidney Kimmel Comprehensive Cancer Center Identifier:
First received: May 5, 2010
Last updated: May 6, 2010
Last verified: May 2010

A novel infrared imaging tool to aid in the clinical detection of atypical pigmented lesions and melanoma is developed. Goals include evaluation of the utility of high-resolution infrared scanning of cutaneous lesions in the diagnosis of pigmented lesions and the identification of high-risk lesions and melanomas.


Study Type: Observational
Study Design: Observational Model: Case-Only
Official Title: Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi

Resource links provided by NLM:

Further study details as provided by Sidney Kimmel Comprehensive Cancer Center:

Estimated Enrollment: 30
Study Start Date: September 2009

Ages Eligible for Study:   10 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

The subject population will be identified in the Department of Dermatology Pigmented Lesion Clinic at the Johns Hopkins Hospital Outpatient Center. Recruited patients will only comprise those requesting a cutaneous pigmented lesion removed or patients that are examined and found to have a pigmented lesion that is suspicious for malignancy at the time of their visit, and thus recommended to have a skin biopsy for diagnosis following the standard of care


Inclusion Criteria:

  • Patients seen in the high-risk pigmented lesion clinic, who posses a pigmented lesion with a clinical indication for biopsy

Exclusion Criteria:

  • None
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01118832

United States, Maryland
Johns Hopkins Medicine Recruiting
Baltimore, Maryland, United States, 21287
Contact: Rhoda Alani, MD    617-638-5517   
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Boston University
Principal Investigator: Rhoda Alani, MD Johns Hopkins University
  More Information

No publications provided

Responsible Party: Rhoda Alani, Johns Hopkins University Identifier: NCT01118832     History of Changes
Other Study ID Numbers: J0868, NA_00016040
Study First Received: May 5, 2010
Last Updated: May 6, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by Sidney Kimmel Comprehensive Cancer Center:

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas processed this record on February 25, 2015